Liftstream is an executive search recruitment company in the life sciences sector
What would make your employees stay?
Posted in Diversity and Inclusion Consulting, General, Recruitment Market, Workplace Diversity Tagged Amsterdam Biotech Cluster, Biocat Biotech Cluster, Biopolis, BioRN, BioValley Biotech Cluster, Boston Biotech cluster, Cambridge Biotech Cluster, Cancer Bio-Sante, Flanders Biotech Cluster, London Biotech Cluster, Medicon Valley Cluster, Munich Biotech Cluster, New Jersey Biotech Cluster, Oslo Cancer Cluster, Oxford Biotech Cluster, Philadelphia Biotech Cluster, San Francisco Biotech Cluster, Seattle Biotech Cluster Leave a comment
Has investment changed your board?
Posted in Corporate Governance, Diversity and Inclusion Consulting, Uncategorized Tagged Amsterdam Biotech Cluster, Bay Area Cluster, Biopolis, BioRN, BioValley Biotech Cluster, Boston Biotech cluster, Cambridge Biotech Cluster, gender diversity, London Biotech Cluster, Medicon Valley Cluster, Munich Biotech Cluster, New York Biotech Cluster, Oslo Cancer Cluster, Oxford Biotech Cluster, Philadelphia Biotech Cluster, San Francisco Biotech Cluster, Seattle Biotech Cluster, Toronto Canada Biotech Cluster, women on boards Leave a comment
Pfizer and Merck collaborate for cancer immunotherapy
Posted in M&A Finance and Funding, Pharmaceutical business Tagged Amgen, big pharma, BioRN, BMS, Boston Biotech, celgene, immunotherapy, Lung Cancer, Merck, Munich Biotech, oncology, pembrolizumab, Pfizer, Xalkori Leave a comment
How can biotech enhance executive leadership?
Take our short survey and participate in a global gender diversity study
Working in biotech, pharma or venture capital?
Posted in Pharmaceutical business, Workplace Diversity Tagged Amsterdam Biotech, Bay Area Cluster, BioCat, Biopolis, BioRN, biotech, bioValley, Board level, Boston Biotech, Cancer Bio-Sante, Diversity, Flanders Biotech, Global Diversity Survey 2014, leadership, London Biotech, Malaysia Biotech, Medicon Valley, men, Munich Biotech, New Zealand Biotech, One Nucleus, Oxford Biotech, pharma, pharmaceutical, Stevenage Biotech, women Leave a comment
Immatics receives final 22m Euro Tranche of Series D funding
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business Tagged 2015, BioRN, finance, funding, Germany, IMA901, immatics, Munich Biotech, oncology, Paul Higham, phase III clincial studies, RCC, renal cell carcinoma, Series D, Wellington Partners, XPRESIDENT Leave a comment
European biotech clusters must attract executive talent or seek new leaders
Authored by Karl Simpson
Posted in Job Hunting Advice, Pharmaceutical business Tagged academics, Amsterdam Biotech, Bay Area Cluster, BioCat, Biopolis, BioRN, Biotech Clusters, biotechnology, bioValley, Boston Biotech, Bruce Booth, Cancer Bio-Sante, Chairman, commercial, development, Flanders Biotech, Industry, Katrine Bosley, London Biotech, Malaysia Biotech, Medical Devices, medical technology, Medicon Valley, Munich Biotech, New Zealand Biotech, non executive directors, One Nucleus, Oxford Biotech, pharmaceutical, research, Stevenage Biotech Leave a comment
Merck Serono continues impressive standard in gender diversity
Authored by Karl Simpson
Posted in Pharmaceutical business, Workplace Diversity Tagged 20 women leaders in life sciences, Annalisa jenkins, Biologics, BioRN, biotechnology, bioValley, Diversity, Dr Belen Garijo, Elcin Ergun, gender diversity, HBA, infographic, Liftstream, Meeta Gulyani, Merck KGaA, Merck Serono, Munich Biotech, pharmaceutical, Susan Herbert, women Leave a comment
Dr Karl-Ludwig Kley – Merck KGaA – Executive Leadership Series
Posted in Pharmaceutical business Tagged 13 for 13, AZ Electronics, BeiGene, BioRN, CEO, clinical trials, Erbitux, executive, INSPIRE, Karl-Ludwig Kley, Liftstream, Merck KGaA, Merck Serono, restructuring, Stimuvax Leave a comment
Billionaires send Ganymed racing through clinic
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases Tagged ADC, Andreas Strungmann, ATS Beteiligungsverwaltung GmbH, BioRN, bispecific, clinical studies, Dr Ozlem Tureci, EMA, FDA, Ganymed, gastroesophageal cancer, Hexal, IMAB362, IMABs antibodies, Novartis, orphan drug designation, Professor Uger Sachin, Thomas Strungmann, venture capital Leave a comment